Terumo Corporation · TSE:4543
Terumo — Q3 FYE/Mar. 2008 Earnings Presentation
18 slides from Terumo's earnings presentation, 2008
Slide 1: 3rd Quarter Financial Results for FYE/Mar.2008
TERUMO CORPORATION 3rd Quarter Financial Results for FYE/Mar.2008 1
Slide 2: Sales and Profits Enjoyed Double-digit Growth
Sales and Profits Enjoyed Double-digit Growth (Unit : Billion yen) Q3 FYE/Mar. 2007 Q3 FYE/Mar. 2008 Rate of change Net Sales ２０５.１ ２３１.４ 13% Gross Profit (%) １１３.２（55.2%） １２７.５（55.1%） 13% S.G.A Expenses (%) ６８.０(33.2%） ７５.１（32.4%） 10% Operating Income (%) ４５.２（22.0%） ５２.４（22.7%） 16% Ordinary Income
Slide 3: Financial Summary
Financial Summary (Unit : Billion yen) Operating Net Sales Profit & % Income ＋１２.８％ ＋２６.３ 0.7 point increase 231.4 ＋１６.０％ 205.1 ＋７.２ ＋１７.６％ ＋５.２ 22.7％ 22.0％ 52.4 34.8 45.2 29.5 Q3 Q3 Q3 Q3 Q3 Q3 FYE/Mar. FYE/Mar. FYE/Mar. FYE/Mar. FYE/Mar. FYE/Mar. 2007 2008 2007 2008 2007 2008 3
Slide 4: Net Sales (by Region)
Net Sales (by Region) (Unit : Billion yen) ＋６．９％ Outside of Japan ＋７.９ Q3 Q3 ＋２０．４％ FYE/Mar. FYE/Mar. 2007 2008 （+14.6% Excluding impact of foreign exchange) Sales Outside of Japan Rate ４４％→４７％ 123.2 115.3 ＋２１．５％ ＋１４．４％ ＋３１．６％ （＋１１．６％） （＋１３.４％） （＋２３.５％） ＋７.５ ＋５.５ ＋５.４ 42.3 43.5 34.8 38.0 22.5 17.1 J
Slide 5: Net Sales (by Product Group)
Net Sales (by Product Group) (Unit : Billion yen) ＋１０.９％ Q3 Q3 FYE/Mar. FYE/Mar. ＋１１.２ 2007 2008 114.3 ＋２４.２％ ＋７.０％ ＋６.８％ 103.1 ＋１１.３ ＋２.３ 57.8 ＋１.５ 46.5 36.0 23.3 33.7 21.9 General Intervention CV and Home Hospital Vascular Grafts Health Care 5
Slide 6: S.G.A expenses
S.G.A expenses (Unit : Billion yen) S.G.A Expenses Rate ＋７.１ ▲ 0.8 points Q3 Q3 % in FYE/Mar. FYE/Mar. Change change 2007 2008 75.1 Personnel 23.6 26.6 +2.9 12.4% 68.0 Logistics 5.7 6.8 +1.1 18.7% Sales promotion 6.9 7.6 +0.7 9.7% and advertising 33.2％ 32.4％ R&D 11.6 11.8 +0.2 1.4% Others 20.1 22.4
Slide 7: FYE / March 2008 Forecast
FYE / March 2008 Forecast (Unit : Billion yen) FYE/Mar. 2007 FYE/Mar. 2008 Rate of change Net Sales ２７６.４ ３０５.０ １０% Operating Income (%) ５８.５（21.2%） ６５.０（21.3%） １１% Ordinary Income (%) ５８.０（21.0%） ６５.０（21.3%） １２% Net Income ３７.２ ４２.０ １３% Average ＵＳ＄ １１７ yen １１３ yen Exchange rate ＥＵＲ １５０ yen １５９ yen
Slide 8: Topics
Topics Growth strategy for Domestic general hospital products 8
Slide 9: Growth trend seen in a harsh domestic market
Growth trend seen in a harsh domestic market (Billion yen) 180 162.3 billion yen 160 +6.4% Domestic sales +2.1% +4.2% （billion yen） Growth ratio（％） 140 120 100 80 9 Mar. 2005 Mar. 2006 Mar. 2007 Mar. 2008 （Forecast）
Slide 10: General hospital products contribute the current growth
General hospital products contribute the current growth (Billion yen) 100 billion yen 100 +6.3% Domestic General +4.7% Hospital products sales ±0% （billion yen） Growth ratio(％） 80 60 10 Mar. 2005 Mar. 2006 Mar. 2007 Mar. 2008 （Forecast）
Slide 11: Products to lead in the domestic general hospital business
Products to lead in the domestic general hospital business < IV solution products group > < Prefilled syringes > +2.2 billion yen +1.0 billion yen (+6.9%) (+13.7%) Infusion Infusion IV administration pumps solution sets < Blood bags > +2.4 billion yen (+68.8%) 11 Q3 FYE/ Mar. 2007 vs Q3 FYE /Mar. 20
Slide 12: Sales expanding with safe and efficient products
Sales expanding with safe and efficient products (Billion yen) IV solution 40 Infusion pumps Sales Infusion administration sets 30 20 10 m ina tio n preventive conta Those with m e p opular b eco plugs have 0 Mar. Mar. Mar. Mar. Mar. Mar. 2003 2004 2005 2006 2007 2008 （Forecast） 12
Slide 13: Terumo Medical Pranex
Terumo Medical Pranex Training for medical professionals About 8,000 medical professionals have visited the site since the renewal open of April 2007 Practical training in the hospital studio 13
Slide 14: Other topics
Et | | Other topics
Slide 15: DES, "Nobori" acquired CE mark
DES, "Nobori" acquired CE mark • Europe - Sales will start in 4Q - Clinical tests planned after commercialization • Japan - Clinical tests in progress • Asia CE mark - Sales have already started certificate 15
Slide 16: Enjoying good sales
enjoying good sales Winning No.1 share in the domestic market! ◆Contributing to medical economic improvement ‐Supports a variety of needs with a single unit, completing treatment with a small number of catheters Highly pressure-resistant Maintains high passage capability Expands hard, calcificated R
Slide 17: The next mid-term plan will be announced on April 30
The next mid-term plan will be announced on April 30 17
Slide 18: IR Contact
IR Contact TERUMO Corporation Corporate Communication (IR) Dept. E-mail: [email protected] This document contains forward-looking statements that reflect management’s current views with respect to certain future events and financial performance. Actual results may differ materially from those project